Company intelligence / Profile preview
Syndax Pharmaceuticals
Waltham, Massachusetts, United Statessyndax.com ↗
- Ownership
- Public · SNDX
- Employees
- ~270
- Development stage
- Commercial
01
Overview
Syndax Pharmaceuticals has transitioned to a commercial-stage biopharma with two FDA-approved products:
- Revuforj® (revumenib): an oral menin inhibitor for relapsed/refractory acute leukemia with KMT2A rearrangement or NPM1 mutation. Positive pivotal Phase II data in R/R mutant NPM1 AML was announced in late 2024. sNDA filing expected in first half of 2025 based on these results.
- Niktimvo™ (axatilimab-csfr): an anti-CSF1R monoclonal antibody approved for chronic graft-versus-host disease. Additional studies are ongoing for earlier lines of cGVHD therapy and idiopathic pulmonary fibrosis. The company continues to expand its pipeline into additional indications and combinations.[9][2][5]
- Therapeutic areas
- OncologyImmunologyPulmonology
- Modalities
- Small molecules (menin inhibitors)Monoclonal antibodies (anti-CSF1R mAb)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Incyte Corporation – U.S. commercialization partnership for axatilimab/Niktimvo™[2].Eddingpharm International – licensing agreement for entinostat in China[3].UCB – exclusive worldwide license agreement for anti-CSF1R antibody program [7].
04
Financials
- Market cap
- $843.6M
- Total revenue
- $172.4M
- Enterprise value
- $1B
Beyond the preview
Go deeper on Syndax Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syndax Pharmaceuticals.